Com­mer­cial strat­e­gy for Gilead­'s Covid-19 drug-to-be remde­sivir re­mains opaque, as chief O'­Day em­pha­sizes re­spon­si­bil­i­ty

In his open­ing re­marks on Thurs­day, Gilead chief Daniel O’Day did us all a fa­vor, trun­cat­ing his com­men­tary on the quar­ter gone by to set aside more time to dis­cuss in de­tail remde­sivir: the com­pound at the heart of ef­forts to com­bat Covid-19.

But the big ques­tion re­mained — does Gilead plan to gen­er­ate a re­turn on its in­vest­ment in the drug? O’Day did not an­swer that ques­tion di­rect­ly, in­stead, he em­pha­sized the need for re­spon­si­bil­i­ty.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER